Two stocks in Healthcare
Intuitive Surgical vs Eli Lilly and Company: profit, growth, debt and price compared
Eli Lilly and Company is stronger on 4 of 5 figures: profit margin, sales growth, price for its expected profit and price trend. Intuitive Surgical is stronger on none.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Intuitive SurgicalISRG | Eli Lilly and CompanyLLY | |
|---|---|---|
| Net margin | 25.5% | Stronger: 31.9% |
| Revenue growth, past year | +21.70% | Stronger: +38.61% |
| Debt to equity | — | 122.9% |
| Forward P/E | 33.8× | Stronger: 27.2× |
| Dividend yield | — | 0.49% |
| Analysts | Buy · 30 | Buy · 29 |
| From its 200-day average | −2.6% | Stronger: +21.2% |
Share price over the past year
- Intuitive Surgical−23.0%
- Eli Lilly and Company+34.2%
18 Nov 202518 Nov 2026
Intuitive Surgical or Eli Lilly and Company: which is stronger?
- LLY
Which is more profitable?
Eli Lilly and Company keeps more of each sale as profit: 31.9% against 25.5%.
- LLY
Which is growing its sales faster?
Eli Lilly and Company is growing its sales faster: +38.61% over the past year, against +21.70%.
- LLY
Which costs less for the profit it is expected to make?
Eli Lilly and Company costs less for the profit it is expected to make: 27.2× its forward earnings, against 33.8×.
Which pays more in dividends?
Eli Lilly and Company pays 0.49% a year in dividends for what a share costs, where Intuitive Surgical pays none.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- LLY
Which is in the stronger price trend?
Eli Lilly and Company's price is in the stronger trend: 21.2% above its 200-day average, against 2.6% below.
What each company does
ISRGIntuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
Reports results on 21 January 2027
LLYEli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Reports results on 3 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.